Medistim uses cookies to improve your experience on our website. Read more about our Cookie Policy here Dismiss MENU Font size tip Investor relations Investor relations Annual & Quarterly Reports Board of Directors General Assembly Investor Presentations Medistim at Oslo Stock Exchange Share Capital Development Shareholder Structure Get information Results for the Third Quarter 2021 22. Oct 2021 Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9… READ MORE Pivotal consensus statement for Medistim’s transit time flow technology (TTFM) published in Circulation 19. Oct 2021 Circulation – the official journal of the American Heart Association – and one of the highest ranked journals in cardiology and cardiovascular medicine, published a consensus paper by 19 of the world’s highest renowned specialists… READ MORE Results for the Second Quarter and First Half 2021 13. Aug 2021 Total revenues for the quarter ended at MNOK 109.8 (MNOK 82.5) and includes MNOK 5.3 granted by the U.S. Paycheck Protection Program related to COVID-19. Total revenues for the first half ended at MNOK 212.4… READ MORE Adding the popular Pay Per Procedure business model to the MiraQ platform 8. Jun 2021 Medistim utilizes several business models to effectively reach different segments of the US market. In addition to traditional capital investments and purchase of consumables, hospitals can choose to enter leasing agreements or Pay Per Procedure… READ MORE Results for the First Quarter 2021 28. Apr 2021 Sales for the quarter ended at MNOK 102.6 (MNOK 103.1), on par with the sales record set in Q1 last year. Currency neutral, sales increased by 1.5%. Second best quarter ever for operating result (EBIT)… READ MORE Annual Report 2020 29. Mar 2021 Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second… READ MORE Results for the Fourth Quarter and Preliminary Results for 2020 26. Feb 2021 Sales for the quarter ended at MNOK 94.2 (MNOK 95.7), a decrease of 1.6%. Sales for 2020 ended at MNOK 363.1 (MNOK 363.7). Operating result (EBIT) for the quarter ended at MNOK 22.1 (MNOK 19.7)… READ MORE Medistim partners with LivaNova as their new distributor for India 5. Jan 2021 With its population size of about 1,4 billion, India is a large and emerging market for Medistim’s ultrasound devices. Today, about 100,000 coronary bypass (CABG) procedures are performed in India annually, representing a market size… READ MORE Results for the Third Quarter 2020 22. Oct 2020 Sales for the quarter ended at MNOK 83.4 (MNOK 85.5), a decrease of 2,5%. Read the full report and presentation below. Q3 report 2020 Q3 presentation 2020 READ MORE Webinar: Third Quarter Financial Results 8. Oct 2020 Sign up for the upcoming financial report presentation. You're invited to join this presentation on Thursday 22 October at 8 AM CEST. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the third quarter results,… READ MORE Older Entries Products MIRAQ CARDIAC MIRAQ VASCULAR MIRAQ ULTIMATE IMAGING PROBE FLOW PROBES Clinical CARDIAC SURGERY TRANSPLANT SURGERY VASCULAR SURGERY AV ACCESS SURGERY PERIPHERAL BYPASS SURGERY CAROTID ENDARTERECTOMY SURGERY Technology TECHNOLOGY TRANSIT TIME FLOW MEASUREMENT ULTRASOUND IMAGING DOPPLER VELOCITY Medistim ABOUT MEDISTIM PERSONAL DATA PROTECTION POLICY OUR HISTORY MANAGEMENT TEAM CERTIFICATES NEWS INVESTOR RELATIONS OUR DISTRIBUTORS CONTENT PORTAL EDUCATION EVENTS Built with WordPress